Biophan-die neue Microsoft?!
Seite 61 von 113 Neuester Beitrag: 26.07.23 00:01 | ||||
| Eröffnet am: | 15.05.04 09:58 | von: aida73 | Anzahl Beiträge: | 3.824 |
| Neuester Beitrag: | 26.07.23 00:01 | von: MrTrillion3 | Leser gesamt: | 361.086 |
| Forum: | Hot-Stocks | Leser heute: | 17 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 58 | 59 | 60 | | 62 | 63 | 64 | ... 113 > | ||||
Unsere Nano-Dauerempfehlung BIOPHAN konnte sich im vergangenen Monat glatt verdoppeln! Bis auf neue 3-Jahres-Hochs bei USD 2.90 ging es da zuletzt nach oben, seit Ende November des vergangenen Jahres beträgt das Plus sogar rund 200%! Wir hatten Ihnen BIOPHAN zum ersten Mal Ende 2003 zum Kurs von USD 0.38 empfohlen, das bedeutet: Mutige Anleger, die unserem damaligen Rat also gefolgt sind, sitzen heute auf steuerfreien Gewinnen von über 600%!
Das ist ein Wort und hat natürlich auch seinen Hintergrund: Das Nanotech-Unternehmen hat von den US-Behörden ein weiteres Patent erhalten. Dabei handelt es sich um nanomagnetische Abwehrmaterialien, deren Verhalten zudem in einer elektromagnetischen Umgebung analysiert wurde. Diese Materialien unterstützen BIOPHANs Technologie zur Sicherung metallischer Implantate in Kernspintomografen. Hartnäckig halten sich weiterhin auch Gerüchte im Markt, die Branchenprimus BOSTON SCIENTIFIC starkes Interesse an BIOPHAN nachsagen. Aber: Diese spektakulären Kursgewinne lassen Sie sich nun nicht mehr aus der Hand nehmen und stellen zumindest die Hälfte Ihrer Position umgehend glatt. Mit den verbleibenden Stücken spekulieren Sie dann völlig risikolos auf den erfolgreichen Durchbruch der Technologie, der den Aktienkurs in den kommenden Jahren dann noch einmal deutlich nach oben treiben dürfte: Bitte erinnern Sie sich noch einmal an die spektakuläre Kaufstudie der Analysten von Cohen Independant Research, die vergangenen Sommer einen Gewinn je Aktie von USD 2.14 im Jahr 2009 in Aussicht gestellt haben!
Man soviele Oder`s hat ich garnicht aufm Zettel beim Kauf vorhin!;)))))) Maybe .....
solong Basti... www.inselstaat.info
Biophan to Be Issued Two New Patents for Solutions Targeting Enhanced Heart Monitoring and Nanoparticle Coatings
Friday April 1, 4:01 pm ET
Patent Opens the Way for Reducing Danger of MRI Imaging for Existing Pacemaker Recipients
ROCHESTER, N.Y.--(BUSINESS WIRE)--April 1, 2005-- Biophan Technologies, Inc. (OTCBB:BIPH - News), a developer of next-generation biomedical technology, has announced that the U.S. Patent and Trademark Office will issue on April 5 two new patents involving proprietary developments that enable Magnetic Resonance Imaging (MRI) of heart activity and advance the manufacture of nanoparticle coatings for medical devices.
ADVERTISEMENT
The patents describe innovations involving a number of multi-billion-dollar biomedical marketplaces where Biophan holds a significant lead in advanced intellectual property solutions, including nanotechnology and photonic-based solutions for MRI safety and imaging compatibility.
One of the newly issued patents is part of a suite of Biophan patents that cover a wide array of technology solutions in MRI safety for implanted medical devices. This particular patent focuses on the method for use of a photonic, or fiber optic, lead that avoids MRI interference. It is intended for use in numerous biomedical diagnostic applications that require the sensing of electromagnetic fields at the body surface, and the transmission of information about those fields along the photonic lead. This technique is particularly targeted to enable electrocardiogram (EKG) measurements to be made in the imaging environment of an active MRI device.
EKG leads are known to get hot in MRI machines; some reports indicate burns have resulted from EKG devices that are claimed to be MRI compatible. It is often vital to monitor the electrophysiological status of a patient undergoing MRI, especially in a situation where a patient with a pacemaker needs an MRI diagnosis to stage them for a critical cancer operation.
This newly issued patent, and its other photonic catheter patents, have claims that relate to making an MRI-safe and image-compatible EKG lead, using a fiber optic cable which goes directly to the EKG pad on the chest or leg to sense heart rhythms. The Company has demonstrated that fiber optics are safe for use with MRI, and has also developed and patented solutions for making metal wires safe with MRI.
" This is a good example of our comprehensive approach to covering the waterfront by patenting multiple solutions to an important problem such as this," said Michael Weiner, CEO of Biophan. " These multiple patent thickets ensure a high level of patent protection for Biophan and its technology licensees."
Until pacemakers are made MRI safe by pacemaker manufacturers, dedicated physicians will continue to attempt to find ways to reduce the risks associated with giving a pacemaker patient an MRI scan. One of the risks in giving a pacemaker recipient an MRI is the danger that the electrical currents induced in the lead by the MRI gradient field sweeping across the body will induce fibrillation in the patient. Until manufacturers make future products definitively MRI-safe, something needs to be done for the 3 million people with pacemakers who would be put at risk in an MRI scan.
MRI-safe EKG leads can go a long way to reducing the dangers. That is one of the significant benefits offered by this patent. With truly safe MRI EKG leads, patients can be monitored while in the MRI machine, and defibrillated if needed. This is a particularly worrisome problem if the implantable pacemaker lead has problems, including wear or other defects that impede optimal current flow, such as corrosion or partial breakage.
" It is not reasonable to expect every MRI technician to know all this, but it is reasonable to make sure that a pacemaker patient, even one in one thousand, does not die in an MRI coil during a scan," said Mr. Weiner. " The pacemaker industry now has several solutions. It is time for them to take action. It is their ethical imperative."
The other newly issued patent describes specific details that relate to the creation of a layered electromagnetic shielding assembly from nanoparticulates consisting of relatively common materials such as aluminum, iron, nickel, and cobalt. Various medical applications of this technology are under license to Biophan.
Following the most recent issuances, the Company holds a total of 36 issued patents, 6 allowed patents that have been approved for subsequent issuance, with 72 still undergoing the patent examination process. Biophan and its licensors hold a total of 114 U.S. patents, licenses or applications.
" These latest patent issuances lend further support and strength to Biophan's intellectual property portfolio, which we are building with the intent to establish control of a growing number of biomedical markets," said Mr. Weiner. " For example, one of the newly-issued patents has the potential to enable creation of improved diagnostic methods for heart monitoring through the use of new MRI-based techniques. Biophan's solutions in this area could enable doctors to use MRI imaging in cardiac procedures, bringing MRI's advantages in safety and imaging resolution to this critical area of medical care. However, our intellectual property strategy involves patent protection for the widest possible uses and markets for our technologies."
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the " SEC" ). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
--------------------------------------------------
Contact:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
OR
Press Interviews:
Jennifer Gould, 212-843-8037
--------------------------------------------------
Source: Biophan Technologies, Inc.
...aber nochmal nachfragen!?
Auf meine Vermutung hin, daß der starke Kursrückgang im zuvor erfolgten raschen und starken Kursanstieg begründet liegt (daher Gewinnmitnahmen und kein Abverkauf der Aktie) war deine Aussage das du bei Posten von 200.000 Stk. nicht an GWM von Groß- Investoren glaubst!?
Wäre nicht die logische Erklärung, das hier Kasse gemacht wurde um mit dem Gewinn in eine neue aussichtsreiche Aktie einzusteigen, um in kurzer Zeit wieder die Chanche auf massive Gewinne zu generieren!?!?
Einen Short- Angriff oder ein Selloff der Aktie, ist für mich auf Grund der Nachrichtenlage auszuschließen - also welche Situation ergibt sich dann noch aus deiner Sicht!!
Würde mich sehr interessieren und freue mich über deine Antwort;
Greets
Irgendwelche Short-Angriffe zu vermuten, halte ich persönlich für unrealistisch.
Da der Markt die 200.000 Stücke ja ganz gut aufgenommen hat, sehe ich das Ganze aber nicht als sonderlich Besorgnis erregend an. Meine Hoffnung, die 1,50€ nochmal zu sehen, bleibt aber....!:-)
Ich vermutet mal das vielleicht schon nächste Woche die News mit BSX kommt nachdem am 5 April das Patent offiziell anerkannt ist. Der Deal war ja vermutlich eh schon in trocknen Tüchern und man musste nur noch auf die Anerkennung der Patente warten.
Dann wirds bald Dollars regnen, wenn BSX ihren Taxus Stent mit unserer Biophanbeschichtung MRI sichtbar machen will :))
Es ist zwar nicht das,was sich einige erhofft haben aber jedes Patent ist wichtig und erhöht den Wert.
weiterhin erhöht Micheal Weiner den Druck damit auf die Herzschrittmacherhersteller.Klar sind es Mosaiksteine aber das Bild ist fast voll und das waren zwei wichtige Steine, um ein komplettes Bild zu bekommen.Ich,für mein Teil,freue mich auf nächste Woche.Jeder Tag mit Biohan, ist und wird sehr spannend.
Montag eröffnen wir bei ca 2,14 und und dann bin ich guter Stimmung für die nächsten Tage.
Das ist ein Wort und hat natürlich auch seinen Hintergrund: Das Nanotech-Unternehmen hat von den US-Behörden ein weiteres Patent erhalten. Dabei handelt es sich um nanomagnetische Abwehrmaterialien, deren Verhalten zudem in einer elektromagnetischen Umgebung analysiert wurde. Diese Materialien unterstützen BIOPHANs Technologie zur Sicherung metallischer Implantate in Kernspintomografen. Hartnäckig halten sich weiterhin auch Gerüchte im Markt, die Branchenprimus BOSTON SCIENTIFIC starkes Interesse an BIOPHAN nachsagen. Mit den verbleibenden Stücken spekulieren Sie dann völlig risikolos auf den erfolgreichen Durchbruch der Technologie, der den Aktienkurs in den kommenden Jahren dann noch einmal deutlich nach oben treiben dürfte: Bitte erinnern Sie sich noch einmal an die spektakuläre Kaufstudie der Analysten von Cohen Independant Research, die vergangenen Sommer einen Gewinn je Aktie von USD 2.14 im Jahr 2009 in Aussicht gestellt haben!
bsx wird bald kommen!!!!!!
Die zwei Patente sind meiner Meinung wirklich der Hammer, verstehe nicht das es hier so ruhig bleibt. Da war beim Anti-Antenna-Patent mehr Stimmung!! Ich schieb es mal auf das schöne Wetter!
Ich denke das Biophan hier eine Möglichkeit aufzeigt einen P(e)acemaker absolut MRI-Sicher zu gestalten. Das Problem mit den Anschlusskabel und der Gestaltung des gesamten Gerätes dürfte mit diesen Patenten gelöst sein.
Wenn ich Hersteller solcher Geräte wäre, so würde es mir den Angstschweiß auf die Stirn treiben, wenn ich sehe das diese Patente von meiner Konkurrenz genutzt werden können.
Und da Medtronic und Co über ausreichend finanzielles Potential verfügt, mache ich mir um Biophan keine Sorgen!!
cultom w.o.
Es muss eine Meldung mit einem Global Player her. Und solange die nicht kommt, wächst das Risiko auf dem aktuellen Niveau und der Kurs wird nachgeben!
Just my opinion.
hatte mike mit einer e-mail auf die vorkommnisse in deutschland(200k) aufmerksam gemacht,
wöfür er sich auch sehr bedankt hatte und er ist für mögliche shortattacken gerüstet.
lassen wir uns überraschen
http://www.mainzelahr.de/smile/big/smily177.gif
Biophan wird sehr heiß werden und einen Markt beleben,in dem Biophan ein ernsthafter und wichtiger Schwerpunkt sein wird.
Mk=200mille$??? Nein 2009 Mk 10mrd$.So wird sich das abspielen.
auf eine sehr erfogreiche Woche!!Und nicht vergessen,wie schnell sich Biophan von dieser Konsolidierung erholt hat.Es wird jetzt sehr schnell gehen(nur meine Meinung)
Meiner Meinung nach 2 fundamentale Patente. Erkennt man allein schon an den Kommentaren von MW dazu...
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: Biophan Technologies, Inc.
Biophan Technologies, Inc. Rated 'Outperform,' Target $5.17 by Investrend Affiliate Beacon Equity Research
Monday April 4, 8:30 am ET
NEW YORK--(BUSINESS WIRE)--April 4, 2005--(Investrend Research Syndicate) Biophan Technologies, Inc. (OTCBB: BIPH - News) has been rated " Outperform," with a price target of $5.17 by Investrend Research affiliate Beacon Equity Research. The report is authored by Senior Research Analyst, Shailesh Dhuri.
The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com
In the report, Mr. Dhuri writes, " Biophan Technologies, Inc. (OTCBB: BIPH - News) is an emerging biomedical technology company that provides solutions for making biomedical devices safe for use with the Magnetic Resonance Imaging (MRI) diagnostic procedure. Biophan has strong growth prospects in this growing market as it already has accumulated an impressive portfolio of 114 patents; which include 34 issued, 8 allowed, and 72 applications in process. Biophan's patent portfolio covers areas that include nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics.
MRI is considered one of the most important medical diagnostic tools available today... However, a serious drawback to MRI technology is that it cannot be safely used on patients with pacemakers or other biomedical implants. This is due to the fact that these devices (such as pacemakers and cardioverter/defibrillator/pacemakers) are sensitive to a variety of forms of electromagnetic interference (EMI). These devices contain sensing and logic systems that respond to low-level electrical signals that come from the targeted tissue region of the patient.
Our detailed valuation exercise has led to three different values for the firm, under three market conditions. Under our " Average Conditions" assumptions, we arrive at a target share price of $5.20. Under " Optimistic Conditions," the target share price comes to $13.70. Under " Pessimistic Conditions," the target price works out to $0.80. Overall, by using a weighted-average of the three scenarios, we arrive at a price target of $5.17.
Beacon Equity Research, LLC is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA Institute's (CFAI) stringent ethics and standards of practice guidelines. Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow.
Both Beacon Equity Research and Investrend subscribe to the " Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research Partners has been compensated $18,000 by Biophan Technologies, Inc. for one year of enrollment in its research program.
Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company.
Anyone interested in receiving alerts regarding Biophan research should email contact@investrend.com with " BIPH" in the subject line.
--------------------------------------------------
Contact:
Beacon Equity Research
Jeff Bishop, 972-200-5519
editor@beaconequityresearch.com
www.beaconequityresearch.com
or
Investrend Research
R. Hempel, 718-896-5060
contact@investrend.com
www.investrendresearch.com
or
Biophan Technologies, Inc.
Michael Weiner, 585-214-2441
mweiner@biophan.com
www.biophan.com
gruß aramed
Optionen
| Boardmail an "aramed" |
Wertpapier: Biophan Technologies |
und die Ptsc sringt im bid auf 0,108 von 0,10
ich werde beides machen,wetter und Biophan genießen